First in Man Study of ALX-0651, a Nanobody Inhibiting CXCR4

Healthy Volunteers Clinical Trial

Official title:

A Phase I, Single-centre, Randomised, Single-blinded, Placebo-controlled Single Ascending Dose Study, Followed by an Open-label Extension, Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of ALX-0651, Administered Intravenously to Healthy Male Volunteers

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01374503
• Other study ID #: ALX-0651-1.1/11
• Status: Terminated
• Phase: Phase 1
• First received: June 14, 2011
• Last updated: April 16, 2012
• Start date: June 2011
• Est. completion date: January 2012

Study information

• Verified date: April 2012
• Source: Ablynx
• Contact: n/a
• Is FDA regulated: No
• Health authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
• Study type: Interventional

Clinical Trial Summary

The purpose of this first-in-man Phase I study is to determine whether the CXCR4-inhibitor ALX-0651 is safe and effective after single or multiple intravenous administrations to healthy male volunteers.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 52
• Est. completion date: January 2012
• Est. primary completion date: January 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Healthy male volunteers, aged >= 18 and <= 55 at screening.

• Willing to consent to using an effective contraceptive method for at least 3 months after test substance administration.

• Non-smokers, or ex-smokers abstinent from tobacco for at least 1 year.

• Body mass index (BMI): 19 - 29 kg/m2 (extremes included).

• Haematology and chemistry parameters within normal range or showing no clinically relevant deviations, as judged by the Medical Investigator. For haematology, haemoglobin and white blood cell (WBC) count must be within normal limits. For chemistry, calcium, alkaline phosphatase (ALP), (alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT) and lactate dehydrogenase (LDH) must be within normal limits.

• Normal electrocardiogram, showing no clinically relevant deviations, as judged by the Investigator. QTc <= 450 ms.

• No history or presence of diseases of the kidneys, heart, lungs, liver, gastrointestinal tract or endocrine organs, or other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs.

• No history of clinically relevant allergies.

• Obtained, signed and dated informed consent.

• Ability and willingness to comply with protocol requirements.

Exclusion Criteria:

• Intake of any prescribed systemic or topical medication within 14 days prior to dosing.

• Intake of vitamin A derivates or retinoids within 30 days prior to the start of drug administration.

• History of thrombosis.

• Chronic infection or acute significant infection or fever within the last 5 weeks prior to the start of test substance administration.

• Subjects with any abnormality of the spleen (confirmed by echography) or history of splenic disease, or subjects that underwent splenectomy in the past.

• Blood donation (>500 ml) or a comparable blood loss within three months prior to the start of drug administration.

• Subjects who, in the investigator's opinion, may not be capable of following the study schedule for any reason, with special emphasis on eligibility for the aphaeresis procedure.

• Participation in an investigational drug study within 60 days prior to drug administration, or within less than 6 times the terminal elimination half-life of the test substance used in the respective trial (whichever is longer).

• Malignancy, or prior malignancy, with a disease-free interval of < 5 years after diagnosis and intervention, except curative treatment for non-melanoma skin cancer or resected carcinoma in situ.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Healthy Volunteers

Intervention

Biological:
• ALX-0651
single or multiple (once daily for maximum 3 consecutive days) i.v. administration, 0.003-12 mg/kg
• Placebo
single or multiple i.v. administration

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Ablynx

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of treatment emergent adverse events		until 1 month after study drug administration	Yes
Secondary	maximum plasma concentration (Cmax) of ALX-0651	Plasma concentration of ALX-0651 will be determined at different timepoints between predose and 48 hours after the last study drug administration. The maximum plasma concentration (Cmax) of ALX-0651 will be derived from the resulting plasma concentration versus time plots.	from predose until 48 hours after study drug administration	No
Secondary	CD34 positive cell count in blood		from predose until 14 days after study drug administration	No